Cargando…
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
PURPOSE: To evaluate the mechanisms of how therapeutic upregulation of the transcription factor, CCAAT/enhancer-binding protein alpha (C/EBPα), prevents tumor progression in patients with advanced hepatocellular carcinoma (HCC) and in different mouse tumor models. EXPERIMENTAL DESIGN: We conducted a...
Autores principales: | Hashimoto, Ayumi, Sarker, Debashis, Reebye, Vikash, Jarvis, Sheba, Sodergren, Mikael H., Kossenkov, Andrew, Sanseviero, Emilio, Raulf, Nina, Vasara, Jenni, Andrikakou, Pinelopi, Meyer, Tim, Huang, Kai-Wen, Plummer, Ruth, Chee, Cheng E., Spalding, Duncan, Pai, Madhava, Khan, Shahid, Pinato, David J., Sharma, Rohini, Basu, Bristi, Palmer, Daniel, Ma, Yuk-Ting, Evans, Jeff, Habib, Robert, Martirosyan, Anna, Elasri, Naouel, Reynaud, Adeline, Rossi, John J., Cobbold, Mark, Habib, Nagy A., Gabrilovich, Dmitry I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756351/ https://www.ncbi.nlm.nih.gov/pubmed/34407972 http://dx.doi.org/10.1158/1078-0432.CCR-21-0986 |
Ejemplares similares
-
Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC
por: Yoon, Sorah, et al.
Publicado: (2019) -
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
por: Voutila, Jon, et al.
Publicado: (2017) -
Gene activation of CEBPA using saRNA: Preclinical studies of the first in human saRNA drug candidate for liver cancer
por: Reebye, Vikash, et al.
Publicado: (2018) -
Cannabinoids in the landscape of cancer
por: Mangal, Nagina, et al.
Publicado: (2021) -
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models
por: Huang, Kai-Wen, et al.
Publicado: (2021)